Hypercalcemia Associated with Isolated Bone Marrow Sarcoidosis in a Patient with Underlying Monoclonal Gammopathy of Undetermined Significance: Case Report and Review of Literature

Citation
Gubatan, John, Xiaohui Wang, Abner Louissaint, Anuj Mahindra, and John Vanderpool. 2016. Hypercalcemia Associated with Isolated Bone Marrow Sarcoidosis in a Patient with Underlying Monoclonal Gammopathy of Undetermined Significance: Case Report and Review of Literature. Biomarker Research 4:18.

Published Version
10.1186/s40364-016-0072-5

Permanent link
http://nrs.harvard.edu/urn-3:HUL.InstRepos:27769561

Terms of Use
This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA

Share Your Story
The Harvard community has made this article openly available. Please share how this access benefits you. Submit a story.

Accessibility
Hyperc当地 with isolated bone marrow sarcoidosis in a patient with underlying monoclonal gammopathy of undetermined significance: case report and review of literature

John Gubatan¹*, Xiaohui Wang², Abner Louissaint¹, Anuj Mahindra⁴ and John Vanderpool⁵

Abstract

Background: Bone marrow sarcoidosis is extremely rare. The association between sarcoidosis and lymphoproliferative disorders has been previously speculated, although the diagnosis of sarcoidosis often precedes any hematological derangements.

Case presentation: Here, we report for the first time, a case of a 57-year-old Caucasian woman with a previous diagnosis of monoclonal gammopathy of undetermined significance (MGUS) developing hypercalcemia and renal failure with workup notable for isolated bone marrow sarcoidosis and not multiple myeloma as expected. The patient was successfully managed with prednisone taper therapy with resolution of her hypercalcemia and repeat bone marrow biopsies demonstrating resolving granulomas.

Conclusions: Our case illustrates the diagnostic challenges associated with bone marrow sarcoidosis and suggest that chronic immune stimulation in the bone marrow in the setting of MGUS may be associated with the development of localized sarcoidosis. The long term consequences of steroid therapy targeting sarcoidosis in this patient with underlying MGUS remain unknown. Greater surveillance and closer followup is planned in light of the increased risk of malignant transformation of MGUS into multiple myeloma in the setting of bone marrow sarcoidosis.

Keywords: Hypercalcemia, Bone marrow sarcoidosis, Monoclonal gammopathy of undetermined significance, Lymphoproliferative disorders

Abbreviations: ACE, Angiotensin converting enzyme; Ca, Calcium; CBC, Complete blood cell; Cr, Creatinine; CT, Computed tomography; ED, Emergency department; FDG, Fluorine-18-fluorodeoxyglucose; Hct, Hematocrit; Hgb, Hemoglobin; MGUS, Monoclonal gammopathy of undetermined significance; PCP, Primary care physician; PET, Positron emission tomography; Plt, Platelets; PTH, Parathyroid hormone; PTHrp, Parathyroid hormone related protein; SPEP, Serum protein electrophoresis; UPEP, Urine protein electrophoresis; WBC, White blood cell

* Correspondence: jgubatan@bidmc.harvard.edu
1 Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA
Full list of author information is available at the end of the article

© 2016 The Author(s). Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Extrapulmonary manifestations of sarcoidosis are uncommon. Bone marrow sarcoidosis is infrequently clinically encountered. In the few cases reported, bone marrow involvement most often occurs in the setting of systemic sarcoidosis [1–3]. Isolated bone marrow sarcoidosis is exceedingly rare [4, 5]. The association between sarcoidosis and malignant disease including lymphoproliferative disorders has been previously explored [6, 7]. It has been postulated that chronic immune stimulation associated with chronic active sarcoidosis may lead to lymphoproliferative disorders, termed the “sarcoid-lymphoma syndrome” [7, 8]. In contrast to this temporal relationship, patients with hematologic malignancies for more than a year have been observed to develop sarcoidosis [9]. Herein, we report an unusual case of a patient with four-year history of monoclonal gammopathy of undetermined significance (MGUS) preceding the diagnosis of isolated bone marrow sarcoidosis presenting as hypercalcemia.

Case presentation
A 57-year-old Caucasian woman with a four-year history of monoclonal gammopathy of undetermined significance (MGUS) complained of several weeks of dry mouth, polydipsia and episodes of confusion. Her serum calcium was 14.4 mg/dL when tested at the office of her primary care physician (PCP) and sent to the emergency department (ED) where her exam was remarkable only for dry mucous membranes. Initial labs were notable for Ca 14.4 mg/dL, albumin 5.0 g/dL, PTH 7 pg/mL, and Cr at 1.94. CBC was notable for mild pancytopenia with WBC 3.5 (th/cmm) with normal differential, Hgb 11.7 g/dL, Hct 34.2 (%), and PLT 145,000 (th/cmm). She received a bolus of normal saline and was subsequently admitted to inpatient service. Initially, the patient’s hypercalcemia was attributed to milk-alkali syndrome and her calcium supplements were discontinued. The patient was managed only with IV hydration. The patient’s serum calcium trended down to 10 mg/dL at the time of discharge.

There was a concern for a neoplastic process, particularly myeloma, given her history of MGUS. The patient underwent bone marrow biopsy at the time of discharge, which was remarkable for non-necrotizing granulomas with no findings suggestive of plasma cell dyscrasia or other neoplasms. (Fig. 1a) Two weeks later, the patient’s repeat calcium was 12.7 mg/dL despite adequate fluid intake. The patient was admitted for further evaluation of hypercalcemia and bone marrow granulomas. An extensive hypercalcemia workup was unrevealing. Malignant and infectious etiologies of granulomatous disease in this patient were investigated. Results from repeat SPEP, UPEP, and serum free light chains were unchanged from baseline values. PTHrp was undetectable. PET scan showed no FDG avid lesions. Infectious workup for granulomas was negative. The patient’s hypercalcemia was attributed to the granulomas given exclusion of other potential causes. As a result, a workup for sarcoidosis was pursued, which was notable for elevated ACE 126 and urinary calcium of 256 mg/24 h (Table 1). Chest X-ray and chest CT revealed no intrathoracic lymphadenopathy or pulmonary parenchymal findings (Fig. 2). There was no evidence of sarcoidosis in any other organ.

The patient underwent a rapid prednisone taper over 9 days. After discontinuation of prednisone, she developed hypercalcemia again. She was then treated with a slow prednisone taper for four months with normalization of serum calcium levels. A follow-up bone marrow biopsy 5 months later (1 month after 4-month course of slow prednisone taper) showed partial resolution of granulomas without malignancies. (Fig. 1b) At her follow-up PCP visit, two years after her initial presentation, the patient was overall asymptomatic with normal serum calcium, ACE, and CBC.

![Fig. 1 Bone marrow biopsies demonstrating non-necrotizing granulomas before steroid therapy (100x original magnification) (a) and follow-up bone marrow biopsy 5 months after diagnosis (4 months later after steroid therapy) shows partial resolution of granulomas without evidence of malignancy (200x original magnification) (b)
Discussion

Bone marrow sarcoidosis is rare and previously reported cases mostly involved patients with severe, chronic, and widespread sarcoidosis. Bone marrow biopsies are not routinely performed in the standard workup of sarcoidosis, thus the overall incidence of bone marrow involvement is unknown. One small cohort study [5] estimated the bone marrow involvement of patients with sarcoidosis to be 10% with most patients exhibiting hematologic abnormalities as well as systemic sarcoidosis.

Our case illustrates the diagnostic challenges associated with an atypical and rare manifestation of sarcoidosis. The clinical presentation of bone marrow sarcoidosis is variable, non-specific, and may overlap with those of systemic sarcoidosis which include fever, fatigue, malaise, weight loss, and night sweats. Patients with bone marrow involvement may have associated hematological abnormalities including anemia, leukopenia, and thrombocytopenia [3–5].

Although the diagnosis of sarcoidosis seemed unlikely during the early workup of this patient, three lab abnormalities had some clinical utility and diagnostic value in support of sarcoidosis: elevated ACE serum level, hypercalcemia, and hypercalciuria. ACE levels are elevated in 75% of untreated patients with sarcoidosis and levels tend to correlate with disease activity [10]. One study by Ackermann et al. [11] estimates the prevalence of hypercalcemia in patients with sarcoidosis to be around 2 to 63% depending on the population studied. The study attributed the differences in prevalence of hypercalcemia among sarcoidosis patients to the undulating course of subacute sarcoidosis as well as variability in testing for serum calcium. The study also found that hypercalciuria appeared to be twice as prevalent as hypercalcemia and argued that checking urine calcium should be part of the workup of sarcoidosis.

Given the rare occurrence of bone marrow sarcoidosis, there are currently no randomized controlled trials comparing treatment modalities. However, a review of the relevant literature presents four case reports of patients with biopsy-proven bone marrow sarcoidosis demonstrating various approaches to treatment. One case report by Saliba et al. [12] involved a 71-year-old woman with severe hypercalcemia and isolated BM sarcoidosis. The patient was treated with IV saline hydration and her hypercalcemia resolved after five days. The patient did not undergo steroid therapy as her hypercalcemia did not reoccur. Another case report by Slart et al. [13] involved a 49-year-old man with lytic lesions and symptomatic hypercalcemia found to have bone marrow sarcoidosis and subacute pulmonary sarcoidosis. The patient responded well to a steroid taper. A third case report by del Mar Osma et al. [14] involved 44-year-old woman with isolated bone marrow sarcoidosis presenting with weakness, weight loss, and nightly fevers. The patient was started on adalimumab with subsequent resolution of her constitutional symptoms. The final case report by Patel et al. [15] involved a 42-year-old man with diabetes and systemic sarcoidosis with bone marrow involvement presenting with anemia,

| Table 1 Calcium studies during patient’s two hospitalizations |
|-----------------|-----------------|-----------------|
| Lab Value (Units) | 1st Admission | 2nd Admission | Normal Values |
| Ca (mg/dL) | 14.3 | 12.7 | 8.5–10.5 |
| iCa (mg/dL) | 1.73 | 1.14 | 1.14–1.30 |
| PTH (pg/mL) | 7 | 5 | 100–600 |
| Urine Ca | – | 256 mg/24 h | Female: < 250 mg/24 h |
| 1,25 OH Vit D (ng/mL) | – | 49 pg/mL | – |
| 25 OH Vit D (ng/mL) | 44 ng/mL | – | 25–80 |
| PO4 (mg/dL) | 5 | 2.5 | 2.6–4.5 |
| Albumin (g/dL) | 5 | 5 | 3.3–5.0 |
| Creatinine | 1.94 | 1.23 | 0.60–1.50 |

![Fig. 2 Imaging Results: Normal Chest X-Ray (a) and Chest CT without evidence of intrathoracic lymphadenopathy or pulmonary parenchymal lesions (b)](image)
thrombocytopenia, and splenomegaly. The patient was initially treated with steroids, but discontinued due to complications with his diabetes. The patient was treated with adalimumab and his hematologic parameters improved after two courses of therapy.

These case reports highlight that the therapeutic approach to patients with bone marrow sarcoidosis depend on clinical presentation. Patients with symptomatic hypercalcemia appear to respond well to IV saline hydration and in severe cases may require steroid taper therapy. Ackermann et al. [11] recommended starting corticosteroid treatment if total corrected calcium rises beyond 3 mmol/l (12 mg/dl) or at lower levels if patients become symptomatic. Patients with constitutional symptoms, systemic sarcoidosis, or contraindications to steroid therapy may respond better to management with adalimumab. In our patient, IV saline therapy had minimal effects on serum calcium. The patient was started on a rapid steroid taper for 10 days with improvements in serum calcium. Upon discontinuation of the steroids, the patient’s hypercalcemia reoccurred. The patient was managed with a second, but slow taper of steroids for four months. The patient’s hypercalcemia and serum ACE levels normalized and continue to remain stable.

An intriguing aspect of this case report involves the potential relationship with the patient’s underlying MGUS. The association between sarcoidosis and the increased risk of malignancy particularly lymphoproliferative disorders has been previously examined [6–8] and case reports with patients with sarcoidosis and MGUS and multiple myeloma have been previously reported. Likewise, it has been hypothesized that the risk of multiple myeloma is increased in patients with sarcoidosis and a more rapid progression from MGUS to multiple myeloma has been observed in the few cases reported [14–16]. In virtually all of these cases, the diagnosis of sarcoidosis preceded or occurred concurrently with that of MGUS. In our patient, the diagnosis of sarcoidosis occurred four years after that of MGUS. It may be possible that the patient developed subacute bone marrow sarcoidosis years before her diagnosis of MGUS, but only came to attention recently after presenting with hypercalcemia. Alternatively, both conditions may have developed concurrently, with her bone marrow sarcoidosis remaining quiescent until her hypercalcemia became clinically significant. Finally, our patient’s case may represent a situation in which MGUS preceded the development of sarcoidosis. Indeed, a review of her CBC through the years including those years prior to her admission when she was only diagnosed with MGUS would seem to reinforce this later point. (Table 2) Previous CBCs were normal for multiple preceding years and she only had pancytopenia on presentation for admission with hypercalcemia secondary to bone marrow isolated sarcoidosis.

Sarcoidosis has been observed to develop in patients with hematologic malignancies with some investigators attributing this to the use of immunosuppressive therapy targeted at the underlying malignancy [17, 18]. Aside from her known MGUS, our patient has never had any malignant disease and was never treated with chemotherapy or immunosuppressives. This raises the possibility that MGUS, in addition to hematologic malignancies, may also be a risk factor in the development of sarcoidosis. It may be possible that the abnormal bone marrow milieu in this patient with MGUS had an impact on the local development of granulomas.

**Conclusions**

In conclusion, isolated bone marrow sarcoidosis is rare and can be a diagnostic challenge. The clinical suspicion for sarcoidosis should be raised in patients with underlying hematologic disorders or malignancies. Due to the rarity of the condition, long terms outcomes in such patients are unclear. Surveillance and regular follow-up is planned in view of the possibility of progression to multiple myeloma or another lymphoproliferative disorder.

---

### Table 2: Complete blood count (CBC) studies in preceding years, upon admission, and post-steroid treatments

| Parameters (units) | 4 years Before Admission | 3 years Before Admission | Last CBC Before Admission | At Admission 8/25/2010 | At Discharge 9/3/2010 | After 1st steroid taper 09/20/10 | After 2nd steroid taper 01/18/11 | PCP Visit 6/13/2012 | Normal Values |
|-------------------|--------------------------|--------------------------|---------------------------|------------------------|------------------------|-------------------------------|-------------------------------|------------------|---------------|
| HGB (g/dL)        | 13.7                     | 14.1                     | 12.3                      | 11.7                   | 11.5                   | 10.4                          | 12.8                          | 13.5             | 12.0–16.0     |
| HCT (%)           | 39.4                     | 42                       | 35.8                      | 34.2                   | 33.5                   | 31                            | 37.5                          | 40.6             | 36.0–46.0     |
| PLT (th/cmm)      | 198                      | 225                      | 193                       | 145                    | 210                    | 198                           | 157                           | 188              | 150–400       |
| WBC (th/cmm)      | 9.2                      | 6                        | 64                        | 3.5                    | 3.6                    | 7.4                           | 4.7                           | 3.8              | 4.5–11.0      |
| Poly (%)          | 79                       | 60                       | –                         | 61                     | 62                     | 94                            | 83                            | 57               | 40–70         |
| Lymphs (%)        | 18                       | 34                       | –                         | 28                     | 25                     | 5                             | 13                            | 33               | 22–44         |
| Monos (%)         | 3                        | 4                        | –                         | 10                     | 11                     | 1                             | 3                             | 8                | 4.0–11.0      |
| Eos (%)           | 0                        | 1                        | –                         | 1                      | 1                      | 0                             | 0                             | 1                | 0–8           |
| Basos (%)         | 0                        | 1                        | –                         | 0                      | 1                      | 0                             | 1                             | 1                | 0–3           |
Acknowledgments
No additional acknowledgements.

Funding
Harvard Open-Access Publishing Equity (HOPE) fund for funding support of article processing charge.

Availability of data and materials
All data is presented in main paper. Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

Authors’ contributions
John Gubatan prepared case report and review of literature and drafted the manuscript, John Vanderpool was the patient’s primary care physician, obtained patient consent, and supervised in drafting of manuscript, Xiaohui Wang was endocrinologist involved in the patient’s case and provided data in Table 1, Abner Louissaint was pathologist involved in the patient’s case and provided photos of bone marrow biopsies, Anuj Mahindra was hematologist/oncologist involved in the patient’s case and provided guidance in drafting manuscript. All authors interpreted the results and contributed to critical review of the manuscript; John Gubatan had full access to all of the data in the study and takes responsibility for the integrity of the data.

Competing interests
The authors declare that they have no competing interests.

Consent for publication
Informed consent was obtained from the patient to report individual patient data and for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Ethics approval and consent to participate
Not applicable.

Author details
1Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Boston, MA 02215, USA. 2Hallmark Health Medical Associates, Melrose-Wakefield Hospital, Reading, MA, USA. 3Department of Pathology, Massachusetts General Hospital, Boston, MA, USA. 4Division of Hematology and Oncology, University of California San Francisco Medical Center, San Francisco, CA, USA. 5Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.

Received: 26 May 2016 Accepted: 6 September 2016
Published online: 15 September 2016

References
1. Baughman RP, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001;164(10):1885–9.
2. Browne PM, Sharma OP, Salkin D. Bone marrow sarcoidosis. JAMA. 1978;240(24):2654–5.
3. Patel Supen R. Systemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report*. J Med Case Reports. 2009;3:8573.
4. Adedayo AO, Grill GA, Bellot P. Severe refractory sarcoidosis in a 64-year-old man with persistent leukopenia. West Indian Med J. 2003;52(1):56–8.
5. Yanardag H, et al. Bone marrow involvement in sarcoidosis: an analysis of 50 bone marrow samples. Haematologica. 2002;87(4):419.
6. Brincker H. Coexistence of sarcoidosis and malignant disease: causality or coincidence? Sarcoidosis. 1989;6(1):31.
7. Goswami T, et al. The sarcoid-lymphoma syndrome. Clin Lymphoma Myeloma Leuk. 2010;10(4):241–7.
8. Saad T, Aignon-Levin N, Shoenfeld Y. Chronic stimulation of the immune system in sarcoidosis and monoclonal gammapathy of undetermined significance. Haerufash. 2009;18(12):809.
9. Cohen PR, Kuzrock R. Sarcoidosis and malignancy. Clin Dermatol. 2007;25(3):326–33.
10. Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis–its value in present clinical practice. Ann Clin Biochem. 1989;26:13–8.
11. Ackermann D. Hypercalcemia in sarcoidosis–case report, prevalence, pathophysiology and therapeutic options. Therapeutische Umschau Revue thérapeutique. 2007;64(5):281.
12. Saliba A, Wald R, Elias MS. Recurrent severe hypercalcemia caused by bone marrow sarcoidosis. Am J Med Sci. 2005;330(3):147–9.
13. Slatt RM, et al. Lytic skull lesions and symptomatic hypercalcemia in bone marrow sarcoidosis. J Intern Med. 1999;246(1):117–20.
14. Del Mar Osma M, Francisco Jose D. “Marrow noncaseating granulomas: sarcoidosis”. Blood. 2012;119(7):1622.
15. Sharma AM, Fried J, Sharma OP. "Monoclonal gammapathy of undetermined significance in sarcoidosis. Two case reports". Sarcoidosis. 1992;9(1):70.
16. Sen F, Mann KP, Jeffrey Medeiros L. "Multiple myeloma in association with sarcoidosis: a case report and review of the literature." Arch Pathol Lab Med. 2002;126(3):365–8.
17. Merchant TE, Filippat DA, Yahalom J. Sarcoidosis following chemotherapy for Hodgkin’s disease. Leukemia & lymphoma. 1994;13(3–6):339–47.
18. Haran MZ, Feldberg E, Berrebi A. Lymphoma masking sarcoidosis. Leukemia & lymphoma. 2002;43(8):1709–10.